Logo image of HOTH

HOTH THERAPEUTICS INC (HOTH) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:HOTH - US44148G2049 - Common Stock

1.04 USD
-0.03 (-2.8%)
Last: 12/24/2025, 7:36:41 PM
1.05 USD
+0.01 (+0.96%)
After Hours: 12/24/2025, 7:36:41 PM
Fundamental Rating

2

HOTH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. The financial health of HOTH is average, but there are quite some concerns on its profitability. HOTH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HOTH had negative earnings in the past year.
In the past year HOTH has reported a negative cash flow from operations.
In the past 5 years HOTH always reported negative net income.
In the past 5 years HOTH always reported negative operating cash flow.
HOTH Yearly Net Income VS EBIT VS OCF VS FCFHOTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

HOTH has a Return On Assets of -131.58%. This is amonst the worse of the industry: HOTH underperforms 84.90% of its industry peers.
HOTH's Return On Equity of -147.77% is on the low side compared to the rest of the industry. HOTH is outperformed by 70.83% of its industry peers.
Industry RankSector Rank
ROA -131.58%
ROE -147.77%
ROIC N/A
ROA(3y)-118.92%
ROA(5y)-124.88%
ROE(3y)-143.37%
ROE(5y)-145.96%
ROIC(3y)N/A
ROIC(5y)N/A
HOTH Yearly ROA, ROE, ROICHOTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HOTH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HOTH Yearly Profit, Operating, Gross MarginsHOTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

HOTH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HOTH has more shares outstanding
HOTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HOTH Yearly Shares OutstandingHOTH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
HOTH Yearly Total Debt VS Total AssetsHOTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

HOTH has an Altman-Z score of -4.38. This is a bad value and indicates that HOTH is not financially healthy and even has some risk of bankruptcy.
HOTH has a worse Altman-Z score (-4.38) than 61.46% of its industry peers.
HOTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.38
ROIC/WACCN/A
WACCN/A
HOTH Yearly LT Debt VS Equity VS FCFHOTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

HOTH has a Current Ratio of 8.81. This indicates that HOTH is financially healthy and has no problem in meeting its short term obligations.
HOTH has a better Current ratio (8.81) than 76.56% of its industry peers.
HOTH has a Quick Ratio of 8.81. This indicates that HOTH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of HOTH (8.81) is better than 77.08% of its industry peers.
Industry RankSector Rank
Current Ratio 8.81
Quick Ratio 8.81
HOTH Yearly Current Assets VS Current LiabilitesHOTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

HOTH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.30%, which is quite impressive.
EPS 1Y (TTM)20.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HOTH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.53% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.12%
EPS Next 2Y24.4%
EPS Next 3Y13.53%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HOTH Yearly Revenue VS EstimatesHOTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M 400M
HOTH Yearly EPS VS EstimatesHOTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HOTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HOTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HOTH Price Earnings VS Forward Price EarningsHOTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HOTH Per share dataHOTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

HOTH's earnings are expected to grow with 13.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.4%
EPS Next 3Y13.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HOTH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

HOTH THERAPEUTICS INC

NASDAQ:HOTH (12/24/2025, 7:36:41 PM)

After market: 1.05 +0.01 (+0.96%)

1.04

-0.03 (-2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-26 2026-03-26/amc
Inst Owners8.06%
Inst Owner Change387.71%
Ins Owners3.57%
Ins Owner Change9.41%
Market Cap16.13M
Revenue(TTM)N/A
Net Income(TTM)-12.16M
Analysts82.86
Price Target4.59 (341.35%)
Short Float %4.02%
Short Ratio1.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-106.58%
Min EPS beat(2)-194.12%
Max EPS beat(2)-19.05%
EPS beat(4)1
Avg EPS beat(4)-49.94%
Min EPS beat(4)-194.12%
Max EPS beat(4)15.21%
EPS beat(8)4
Avg EPS beat(8)-13.78%
EPS beat(12)7
Avg EPS beat(12)-5.15%
EPS beat(16)10
Avg EPS beat(16)-1.59%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.5%
PT rev (3m)12.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.96
P/tB 1.96
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0
BVpS0.53
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -131.58%
ROE -147.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-118.92%
ROA(5y)-124.88%
ROE(3y)-143.37%
ROE(5y)-145.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.81
Quick Ratio 8.81
Altman-Z -4.38
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.23%
EPS Next Y60.12%
EPS Next 2Y24.4%
EPS Next 3Y13.53%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-61.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.09%
OCF growth 3YN/A
OCF growth 5YN/A

HOTH THERAPEUTICS INC / HOTH FAQ

What is the fundamental rating for HOTH stock?

ChartMill assigns a fundamental rating of 2 / 10 to HOTH.


Can you provide the valuation status for HOTH THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to HOTH THERAPEUTICS INC (HOTH). This can be considered as Overvalued.


Can you provide the profitability details for HOTH THERAPEUTICS INC?

HOTH THERAPEUTICS INC (HOTH) has a profitability rating of 0 / 10.